Response to Weidhaas and Slack re: Comments on "The role of rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing".
作者信息
Risch Harvey A, Berchuck Andrew, Pharoah Paul D P
出版信息
Clin Cancer Res. 2011 Oct 15;17(20). doi: 10.1158/1078-0432.CCR-11-1504.
Abstract
摘要
相似文献
1
Response to Weidhaas and Slack re: Comments on "The role of rs61764370 in invasive epithelial ovarian cancer: implication for clinical testing".对魏德哈斯和斯莱克关于《rs61764370在侵袭性上皮性卵巢癌中的作用：对临床检测的启示》评论的回应
Clin Cancer Res. 2011 Oct 15;17(20). doi: 10.1158/1078-0432.CCR-11-1504.
2
Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer.评估 KRAS 基因多态性 LCS6(rs61764370) 在伊拉克卵巢癌女性中的作用。
Arch Razi Inst. 2022 Feb 28;77(1):205-211. doi: 10.22092/ARI.2021.356992.1956. eCollection 2022 Feb.
3
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.KRAS rs61764370 在浸润性上皮性卵巢癌中的作用：对临床检测的影响。
Clin Cancer Res. 2011 Jun 1;17(11):3742-50. doi: 10.1158/1078-0432.CCR-10-3405. Epub 2011 Mar 8.
4
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.KRAS变异体rs61764370对卵巢癌或乳腺癌无临床应用价值。
Gynecol Oncol. 2016 May;141(2):386-401. doi: 10.1016/j.ygyno.2015.04.034. Epub 2015 May 2.
5
The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.Kras 基因 3'-UTR 多态性与癌症风险的相关性及其对转移性结直肠癌患者抗 EGFR 治疗反应的影响：一项荟萃分析。
Onco Targets Ther. 2014 Aug 25;7:1487-96. doi: 10.2147/OTT.S65496. eCollection 2014.
6
rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis.高加索人群中Kras基因rs61764370多态性与癌症风险的荟萃分析
J Cancer Res Ther. 2016 Apr-Jun;12(2):699-704. doi: 10.4103/0973-1482.147379.
7
Association between rs61764370, rs9266, and rs140080026 polymorphisms of the KRAS gene and breast cancer risk in a Mexican population.KRAS 基因 rs61764370、rs9266 和 rs140080026 多态性与墨西哥人群乳腺癌风险的关联。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(21):6454-6464. doi: 10.26355/eurrev_202111_27088.
8
No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.没有证据表明 let-7 微 RNA 结合位点或 KRAS 其他常见变异与子宫内膜异位症风险存在遗传关联。
Hum Reprod. 2012 Dec;27(12):3616-21. doi: 10.1093/humrep/des329. Epub 2012 Sep 25.
9
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer.KRas-LCS6 多态性对卵巢癌的结局没有影响。
Am J Cancer Res. 2012;2(3):298-308. Epub 2012 Apr 21.
10
KRAS rs61764370 in Epithelial Ovarian Cancer-Letter.
Clin Cancer Res. 2011 Oct 15;17(20):6600; author reply 6601. doi: 10.1158/1078-0432.CCR-11-1195.
引用本文的文献
1
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.KRAS变异体rs61764370对卵巢癌或乳腺癌无临床应用价值。
Gynecol Oncol. 2016 May;141(2):386-401. doi: 10.1016/j.ygyno.2015.04.034. Epub 2015 May 2.
本文引用的文献
1
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.KRAS rs61764370 在浸润性上皮性卵巢癌中的作用：对临床检测的影响。
Clin Cancer Res. 2011 Jun 1;17(11):3742-50. doi: 10.1158/1078-0432.CCR-10-3405. Epub 2011 Mar 8.
2
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.卵巢癌中的 KRAS 变异作为癌症风险的遗传标志物。
Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20.
3
Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.评估阳性报告为假的概率：分子流行病学研究方法
J Natl Cancer Inst. 2004 Mar 17;96(6):434-42. doi: 10.1093/jnci/djh075.
Zotero 插件